EPISODE · Jun 21, 2024 · 13 MIN
MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded
from MPR Weekly Dose
Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna's next-gen COVID-19 vaccine; Farxiga approval expanded.
Embed this episode
Ready to play
MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded
0:00
13:30
1×
No transcript for this episode yet
Similar Episodes
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 13 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on June 21, 2024.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!